SR 59230A

SR 59230A is a beta blocker that is used in scientific research. It is a selective antagonist of the Beta-3 adrenergic receptor, which is a type of G protein-coupled receptor found in adipose tissue and the gastrointestinal tract.

History

SR 59230A was first synthesized and studied by the French pharmaceutical company Sanofi. It was developed as part of a research program aimed at discovering new treatments for obesity and diabetes. The compound was first described in the scientific literature in 1993.

Pharmacology

SR 59230A is a potent and selective antagonist of the Beta-3 adrenergic receptor. It has a high affinity for this receptor subtype, with a Ki value of 0.7 nM. The compound has much lower affinity for the Beta-1 and Beta-2 receptors, making it a useful tool for studying the function of the Beta-3 receptor.

Uses

In scientific research, SR 59230A is used to study the role of the Beta-3 adrenergic receptor in various physiological processes. It has been used in studies investigating the regulation of lipolysis and thermogenesis in adipose tissue, the control of gastrointestinal motility, and the potential therapeutic applications of Beta-3 receptor agonists in the treatment of obesity and diabetes.

Side Effects

As a research compound, SR 59230A is not used in humans and therefore its side effects are not well characterized. However, studies in animals have suggested that it may cause an increase in heart rate and blood pressure, similar to other beta blockers.

See Also

• Beta blocker
• Beta-3 adrenergic receptor
• G protein-coupled receptor
• Sanofi

‎